Lysophosphatidylcholine (LPC) is increasingly recognized as a key marker/factor positively
associated with cardiovascular and neurodegenerative diseases. However, findings from …

There is an increasing number of neurologic disorders found to be associated with loss
and/or dysfunction of the CNS myelin sheath, ranging from the classic demyelinating …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown cause.
Absence of specific targets and biomarkers compromise the development of new therapeutic …

Based on increasing evidence suggesting that MS pathology involves alterations in
bioactive lipid metabolism, the present analysis was aimed at generating a complex serum …

Autotaxin (ATX) is a soluble extracellular enzyme that is abundant in mammalian plasma
and cerebrospinal fluid (CSF). It has two known enzymatic activities, acting as both a …

Several years after its isolation from melanoma cells, an increasing body of experimental
evidence has established the involvement of Autotaxin (ATX) in the pathogenesis of several …

Growing evidence suggests an essential role of neuroinflammation in behavioral
abnormalities associated with hepatic encephalopathy (HE). Here, we report the …

Lysophospholipids (LPLs), such as lysophosphatidic acid (LPA), sphingosine 1-phosphate
(S1P), and lysophosphatidylserine (LysoPS), are attracting attention as second-generation …

Introduction: Autotaxin (ATX) is a secreted enzyme that hydrolyzes lysophosphatidylcholine
to lysophosphatidic acid (LPA) and choline. The ATX/LPA axis has received increasing …

Accumulating evidence suggests that lysophospholipids (LPL) serve as lipid mediators that
exert their diverse pathophysiological functions via G protein-coupled receptors. These …